Literature DB >> 28730260

Longer survival of a patient with glioblastoma resected with 5-aminolevulinic acid (5-ALA)-guided surgery and foreign body reaction to polyglycolic acid (PGA) suture.

Raluca Maria Munteanu1, Lucian Eva, Bogdan IonuŢ DobrovăŢ, Alin Constantin Iordache, Liviu Pendefunda, Nicoleta Dumitrescu, Doina Mihăilă, Cristina Maria Gavrilescu, Elena Şapte, Ion Poeată.   

Abstract

In recent years, there is a growing evidence that using 5-aminolevulinic acid (5-ALA)-guided resection of a cerebral glioblastoma, associated with chemoradiotherapy determine a prolonged survival of these patients, even though this period do not exceed 15 months. 5-ALA is a natural biochemical precursor of heme that is metabolized to fluorescent porphyrins, particularly protoporphyrin IX (PPIX) and no foreign reaction were noted until now. However, foreign body reaction developing in neurosurgery is documented in a few number of cases to suture material, surgical hemostatic material, or surgical glove starch, but up to now we could not find any article about granulomatous inflammation to polyglycolic acid (PGA) suture after brain tumor resection. Here we present a case of a delayed foreign body granuloma to PGA suture diagnosed after 10 months following fluorescence-guided surgery with 5-ALA for resection of a cerebral glioblastoma that was difficult to diagnosis both clinically and on magnetic resonance imaging (MRI). Moreover, the survival time was longer. We correlate the appearance of foreign body granuloma with the patient's persistent pre- and postoperative lymphocytosis. We also suggest that the chronic inflammation inhibited the proliferation of any tumoral cells which could remain in the tumor bed because we did not noticed on serial MRI scans a rapidly tumor growth during the first 10 months after the initial surgery as we have expected to be for a glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28730260

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  6 in total

1.  Two cases of granuloma mimicking local recurrence after pulmonary segmentectomy.

Authors:  Mikio Okazaki; Yoshifumi Sano; Yu Mori; Nobuhiko Sakao; Syungo Yukumi; Hisayuki Shigematsu; Hironori Izutani
Journal:  J Cardiothorac Surg       Date:  2020-01-08       Impact factor: 1.637

2.  Microvesicles and Microvesicle-Associated microRNAs Reflect Glioblastoma Regression: Microvesicle-Associated miR-625-5p Has Biomarker Potential.

Authors:  Natalia Simionescu; Miruna Nemecz; Anca-Roxana Petrovici; Ioan Sebastian Nechifor; Razvan-Cristian Buga; Marius Gabriel Dabija; Lucian Eva; Adriana Georgescu
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

3.  The difference of auxiliary examination parameters between margin recurrence and granuloma on enhanced computed tomography after sublobar resection.

Authors:  Jia-Jie Zheng; Zhi-Yong Sun; Dong-Lei Zhang; Xiao-Jing Zhao; Hua-Bing Wei
Journal:  J Thorac Dis       Date:  2022-08       Impact factor: 3.005

4.  A clinical study of efficacy of polyglycolic acid patch in surgery for pneumothorax:a systematic review and meta-analysis.

Authors:  Yuang Mao; Zulei Zhang; Weibiao Zeng; Wenxiong Zhang; Jianyong Zhang; Guangmiao You; Yiping Wei
Journal:  J Cardiothorac Surg       Date:  2020-05-27       Impact factor: 1.637

Review 5.  The Multifaceted Role of Extracellular Vesicles in Glioblastoma: microRNA Nanocarriers for Disease Progression and Gene Therapy.

Authors:  Natalia Simionescu; Radu Zonda; Anca Roxana Petrovici; Adriana Georgescu
Journal:  Pharmaceutics       Date:  2021-06-29       Impact factor: 6.321

6.  Acupoint Embedding of Polyglactin 910 Sutures in Patients with Chronic Pain due to Cervical Spondylotic Radiculopathy: A Multicenter, Randomized, Controlled Clinical Trial.

Authors:  Yu-Xia Chu; Wen-Qiang Cui; Fei Xu; Yuan-Yuan Pan; Yan-Hua Ma; Teng Chen; Si-Jing Wang; Hong-Bo Sun; Yan-Qing Wang; Wen-Shan Sun
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-26       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.